ArticleFrontiers in bioengineering and biotechnology2020
Purification, Characterization, Identification, and Anticancer Activity of a Circular Bacteriocin From
Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 52 citations in OpenAlex.
- Enterococcus thailandicus as an uncommon pathogen in severe lower extremity trauma: a case report.BMC infectious diseases · 2026Article
- Review
- The Role of Lactobacillus Strain Probiotics in Breast Cancer: Strain-Specific Mechanisms and Therapeutic Potential Beyond Probiotics.Probiotics and antimicrobial proteins · 2026Review
- Exploring the frontier of oral nanomedicine in colorectal cancer therapy: Folate-targeted 5FU-Nisin-Selenium conjugates and probiotic-rich diets as a novel approach.Asian journal of pharmaceutical sciences · 2025Article
- Exploiting Salmonella typhimurium as a novel cancer therapeutic agent: from tumor colonization to metabolic engineering.World journal of microbiology & biotechnology · 2025Review
- Characterisation of gut microbiota in Malaysian cancer patients using V3-V4 region of 16S rRNA gene sequencing.Scientific reports · 2025Article
- Susceptibility to Postbiotic Substances-Enterocins of the StrainsPathogens (Basel, Switzerland) · 2025Article
- The Enterococcus secretome inhibits the growth of vancomycin-resistant Enterococcus faecalis V853 with their antiproliferative properties and nanoencapsulation effects.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Selective toxicity of a novel antimicrobial peptide Acidocin 4356 against Pseudomonas aeruginosa and Acinetobacter baumannii in human cell-based in vitro infection models.Scientific reports · 2025Article
- Bacteriocins from Lactic Acid Bacteria Could Modulate the Wnt Pathway: A Possible Therapeutic Candidate for the Management of Colorectal Cancer- AnAnti-cancer agents in medicinal chemistry · 2025Article
- A review on the ecological niche and functional properties of enterococci in health promotion.Current research in food science · 2025Review
- Investigating the Anticancer Properties of Bacterial Toxoid in Combination Vaccines.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Emerging lactic acid bacteria bacteriocins as anti-cancer and anti-tumor agents for human health.Heliyon · 2024Review
- Bacteriocin diversity, function, discovery and application as antimicrobials.Nature reviews. Microbiology · 2024Review
- Friend or Foe: Exploring the Relationship between the Gut Microbiota and the Pathogenesis and Treatment of Digestive Cancers.Microorganisms · 2024Review
- Bacteriocins: potentials and prospects in health and agrifood systems.Archives of microbiology · 2024Review
- Appraisal of postbiotics in cancer therapy.Frontiers in pharmacology · 2024Review
- Development and optimization of curcumin analog nano-bilosomes using 2Drug delivery · 2022Article
- Bacteriocins as Potential Therapeutic Approaches in the Treatment of Various Cancers: A Review of In Vitro Studies.Cancers · 2022Review
- Enterococci-Involvement in Pathogenesis and Therapeutic Potential in Cancer Treatment: A Mini-Review.Pathogens (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New anticancer agents are continually needed because cancerous cells continue to evolve resistance to the currently available chemotherapeutic agents. The aim of the present study was to screen, purify and characterize a hepatotoxic bacteriocin from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.